A comparison of iodopovidone pleurodesis with talc pleurodesis in pleural effusion

Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis.

Chemical pleurodesis using iodized talc is an effective method of treating symptomatic recurrent malignant pleural effusions. Twenty-three effusions occurring in 21 patients treated by this method are described with two illustrative case reports. The procedure eliminated the need for further chest aspiration in all but one instance. The histological appearances of the pleura at intervals after ...

Pleurodesis for malignant pleural effusion: talc, toxicity and where next?

Talc pleurodesis for the treatment of pneumothorax and pleural effusion.

Early interest in the development of pleural symphysis resulted from the desire of surgeons to produce adhesions to facilitate lobectomy.1 Various agents were tried but were found to be of limited value. The indications for pleurodesis have expanded over the years to include the treatment of benign and malignant effusions, the prevention of recurrence of pneumothoraces, and, more recently, to a...

Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion

BACKGROUND Malignant pleural effusions continue to be a common problem in patients with metastatic disease, leading to a significant reduction in quality of life with progressive dyspnea, dry cough, chest pain and reduced physical activity. This study was conducted to compare the efficacy, safety, and outcome of Talc Powder Pleurodesis (TPP) with Povidone-iodine Pleurodesis (PIP) through a ches...

Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion

Background: Iodopovidone is an alternative agent used to promote pleurodesis in patients with malignant pleural effusion (MPE). However, safety is a concern, and many authors still reject its use. Objectives: Our main objective is to describe the occurrence of common and severe adverse events after pleurodesis with two different doses of iodopovidone in patients with MPE. Our secondary objectiv...